Drugs / L-dipivefrin
last change Apr 2026 re-read 2 minutes ago

L-dipivefrin

Investigated by
Insignis Therapeutics, Inc. · Washington University School of Medicine

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07210320 Oct 2025 → Apr 2026 anaphylaxis, food allergy Insignis Therapeutics, Inc. Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as L-dipivefrin “of L-dipivefrin (IN-001) Sublingual Solution Administered Via Spray Device or Oral Syringe” NCT07210320